We are live on ! Find out more

157 hedge funds and large institutions have $1.75B invested in Insmed in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 40

8% less funds holding

Funds holding: 171157 (-14)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

32% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 37

33.81% less ownership

Funds ownership: 144.83%111.01% (-34%)

46% less capital invested

Capital invested by funds: $3.24B → $1.75B (-$1.49B)

57% less call options, than puts

Call options by funds: $5.56M | Put options by funds: $13.1M

Holders
157
Holders Change
-14
Holders Change %
-8.19%
% of All Funds
3.44%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
25
Increased
62
Reduced
40
Closed
37
Calls
$5.56M
Puts
$13.1M
Net Calls
-$7.5M
Net Calls Change
-$2M

INSM Hedge Fund Activity: Q3 2019 in Review

157 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q3 2019, worth a combined $1.75B — down 46% from $3.24B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of INSM and 25 opened new positions — a net loss of 12 holders — while 40 trimmed existing stakes and 62 added.

The largest buyer was Fidelity Investments, adding an estimated $41.6M. The largest seller was Amundi Asset Management US, cutting an estimated $599M.

  • 157 institutional investors held Insmed (INSM) as of Q3 2019, down from 171 in Q2 2019.
  • Funds reported $1.75B of Insmed stock for Q3 2019, down 46% quarter-over-quarter.
  • 25 funds opened new Insmed positions in Q3 2019 and 37 closed out, a net change of -12 holders.
  • The largest Insmed buyer in Q3 2019 was Fidelity Investments, an estimated $41.6M added.
  • The largest Insmed seller in Q3 2019 was Amundi Asset Management US, an estimated $599M sold.

Based on aggregated 13F filings for Q3 2019.